Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Emet S., Dadashov M., Sonsoz M. R., Cakir M. O., Yilmaz M., Elitok A., ...Daha Fazla

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, cilt.356, sa.6, ss.537-543, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 356 Sayı: 6
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.amjms.2018.08.013
  • Dergi Adı: AMERICAN JOURNAL OF THE MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.537-543
  • Anahtar Kelimeler: Sudden cardiac death, Galectin-3, Ventricular arrhythmias, Hypertrophic cardiomyopathy, Risk score, INDEPENDENT MARKER, ABNORMALITIES, ARRHYTHMIAS, DIAGNOSIS, RISK
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Hypertrophic cardiomyopathy is a primary cardiac disease characterized by left ventricular hypertrophy, myocyte hypertrophy and irregularities and interstitial fibrosis in the absence of any cardiac or systemic diseases and may lead to sudden cardiac death (SCD). Galectin-3 is a P-galactoside-binding lectin that has been associated with cardiac fibrosis and inflammation. In this study, we aimed to investigate the relationship between serum galectin-3 levels and the criteria for 5-year sudden death risk, recently defined in the European Society of Cardiology guidelines (2014), in patients with hypertrophic cardiomyopathy.